Safety and activity of RO7300490, a bispecific CD40 agonist targeted to fibroblast activation protein, in patients with advanced solid tumors: a single-arm, multicenter, first-in-human, phase 1 trial - Summary - MDSpire

Safety and activity of RO7300490, a bispecific CD40 agonist targeted to fibroblast activation protein, in patients with advanced solid tumors: a single-arm, multicenter, first-in-human, phase 1 trial

  • By

  • Ignacio Melero

  • Bernhard Reis

  • Corinne Rusterholz

  • Alexandra Epp

  • Nicole A. Kratochwil

  • Chun Wu

  • Michael Hettich

  • Georgios Kazantzidis

  • Natascha Rieder

  • Petra C. Schwalie

  • Solveig Badillo

  • Nadine Kumpesa

  • Andreas Thommen

  • Danielle J. Vugts

  • Victor Moreno

  • Julia Lostes Bardaji

  • Eduardo Castanon Alvarez

  • Carlos E. de Andrea

  • Iben Spanggaard

  • Dae Ho Lee

  • James Spicer

  • Fiona Thistlethwaite

  • Do-Youn Oh

  • Antoine Hollebecque

  • Olivera Cirovic

  • Stefan N. Symeonides

  • May 1, 2026

  • 0 min

Share

Objective:

To evaluate the safety and efficacy of RO7300490, a bispecific CD40 agonist targeting fibroblast activation protein (FAP), in patients with advanced solid tumors.

Key Findings:
  • 0123
Interpretation:

RO7300490 demonstrated manageable safety with a notable incidence of TRAEs but lacked significant clinical efficacy in terms of objective responses. Further clarification on what constitutes 'manageable safety' is recommended.

Limitations:
  • 01
Conclusion:

RO7300490 shows a manageable safety profile but limited efficacy in advanced solid tumors, warranting further investigation in larger trials.

Original Source(s)

Safety and activity of RO7300490, a bispecific CD40 agonist targeted to fibroblast activation protein, in patients with advanced solid tumors: a single-arm, multicenter, first-in-human, phase 1 trial

  • by Ignacio Melero, Bernhard Reis, Corinne Rusterholz, Alexandra Epp, Nicole A. Kratochwil, Chun Wu, Michael Hettich, Georgios Kazantzidis, Natascha Rieder, Petra C. Schwalie, Solveig Badillo, Nadine Kumpesa, Andreas Thommen, Danielle J. Vugts, Victor Moreno, Julia Lostes Bardaji, Eduardo Castanon Alvarez, Carlos E. de Andrea, Iben Spanggaard, Dae Ho Lee, James Spicer, Fiona Thistlethwaite, Do-Youn Oh, Antoine Hollebecque, Olivera Cirovic, Stefan N. Symeonides

  • May 1, 2026

Related Content

Data requirements of an informative, directive, and preventive mobile health application for gastric cancer

Bilateral renal metastasis following radical prostatectomy for prostate cancer: a case report

Stimuli-responsive nanoplatforms for sonodynamic immunotherapy: opportunities and challenges in cancer treatment